Karnofsky Performance Status (KPS)≥ 60, expected survival ≥4 months;
Locally advanced breast cancer (HER2-positive disease and TNBC, ≥cT1c or ≥cN0； HER2-negative，HR positive disease，≥cT2 or ≥cN1；Large primary tumor relative to breast size in a patient who desires breast conservation) ;
According to the RECIST1.1 standard, at least one measurable lesion exists;
You may not be if
Pregnant or lactating women;
Left ventricular ejection fraction less than 50%;
History of malignant tumor and concurrent occurrence of other tumors;
Serious medical pathology, such as congestive heart failure; unstable angina; uncontrolled high risk arrhythmias, and other serious illness or medical condition that may interfere with the study;
Refuse to participate in the study.
Clareo Health | The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy
